In exploring who might benefit from CP, we found that those who had low antibody levels at baseline had a higher increase in COVID-19 antibody levels post-treatment [Day 1/Day 0] (Figure 5A), in line with data demonstrating that those with poor humoral responses such as the elderly or with hematologic malignancies may benefit the most. Here, CP is linked to hematologic disorder.